InvestorsObserver
×
News Home

Do Analysts Agree Tuesday on AbbVie Inc (ABBV) Stock's Target Price?

Tuesday, January 25, 2022 02:16 PM | InvestorsObserver Analysts

Mentioned in this article

Do Analysts Agree Tuesday on AbbVie Inc (ABBV) Stock's Target Price?

Analysts who follow AbbVie Inc (ABBV) on average expect it to gain 10.16% over the next twelve months. Those same analysts give the stock an average rating of Strong Buy. That average rating earns ABBV an Analyst Ranking of 53, which means it ranks higher than 53 of stocks, based on data compiled by InvestorsObserver.

Overall Score - 4.5
Wall Street analysts are rating ABBV a Strong Buy today. Find out what this means to you and get the rest of the rankings on ABBV!

Why are Analyst Ratings Important?

Analysts know the inner workings of the companies they follow better than anyone but the companies’ management. You can learn a lot about a company from studying the financial statements, but analysts ask questions on conference calls and understand the intricacies of each of the businesses they cover. Analysts understand how bad weather in one part of the world can disrupt supply chains, or disrupt shopping patterns. This lets traders make decisions **before** a quarterly report that could be worse than expected. InvestorsObserver aggregates the ratings of all the analysts covering a given stock, takes the average of those ratings and then percentile ranks the averages. That provides a level of granularity that is significantly better than just the three levels provided by traditional buy/hold/sell ratings.

What's Happening With AbbVie Inc Stock Today?

AbbVie Inc (ABBV) stock is up 1.11% while the S&P 500 is down -0.81% as of 2:07 PM on Tuesday, Jan 25. ABBV is higher by $1.47 from the previous closing price of $132.12 on volume of 4,785,891 shares. Over the past year the S&P 500 has gained 13.46% while ABBV is higher by 20.90%. ABBV earned $4.20 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 31.9. Click Here to get the full Stock Report for AbbVie Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App